WCLC Highlights

Share

Program Content

Activities

  • WCLC 2022: Key Studies
    An Expert’s Guide to WCLC 2022: A Preview of the Top Abstracts
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 05, 2022

    Expires: August 04, 2023

  • 2022 WCLC Highlights
    Independent Conference Coverage of the IASLC 2022 World Conference on Lung Cancer
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 25, 2022

    Expires: October 24, 2023

Activities

TROPION-Lung02: Dato-DXd + Pembro and CT
TROPION-Lung02: Initial Results From Phase I Study of Datopotamab Deruxtecan + Pembrolizumab and Platinum Chemotherapy in Advanced NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 18, 2022

Expires: August 17, 2023

Treatment Inequities in NSCLC
Population-Based Assessment of Socioeconomic Treatment Inequities With Biomarker-Guided Targeted Therapy and Immunotherapy for Patients With NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 17, 2022

Expires: August 16, 2023

CodeBreaK101: Sotorasib + RMC-4630
CodeBreaK101: Phase Ib/II Study With Sotorasib + RMC-4630, an SHP2 Inhibitor, in Advanced NSCLC and Other Solid Tumors With KRAS p.G12C Mutation
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 12, 2022

Expires: August 11, 2023

CodeBreaK100/101: Sotorasib + Atezo or Pembro
CodeBreaK100/101: Phase Ib Report of Safety and Efficacy of Sotorasib + Atezolizumab or Pembrolizumab in Patients With Pretreated KRAS G12C–Mutated NSCLC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 16, 2022

Expires: August 15, 2023

DeLLphi-300: Tarlatamab in SCLC
DeLLphi-300: Updated Data From Phase I Study of Tarlatamab, a DLL3-Targeted T-Cell Engager, in Relapsed/Refractory SCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 12, 2022

Expires: August 11, 2023

HUDSON Umbrella Study
HUDSON: Open-Label, Multidrug Umbrella Phase II Study in Patients With Advanced NSCLC After Progression on PD-1/PD-L1 Inhibitor Therapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 18, 2022

Expires: August 17, 2023

Second-Course Pembrolizumab in NSCLC
Results of a Pooled Outcomes Analysis of Phase III Trials Using a Second Course of Pembrolizumab in Advanced NSCLC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 16, 2022

Expires: August 15, 2023

YESS: Personalized Smoking Cessation Support
YESS: Effectiveness of Adding Colocated Personalized Smoking Cessation Support to a Lung Cancer Screening Program
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 18, 2022

Expires: August 17, 2023

CALGB 140503: Sub-Lobar Resection
CALGB 140503 (Alliance): Phase III Trial of Lobar or Sublobar Resection for Peripheral Clinical Stage IA NSCLC With Tumor Size ≤2 cm
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 19, 2022

Expires: August 18, 2023

IMpower010: OS With Adjuvant Atezo in Early-Stage NSCLC
IMpower010: Updated Data of Phase III Trial of Adjuvant Atezolizumab vs BSC in Resected Stage IB-IIIA NSCLC After Adjuvant Chemotherapy
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 16, 2022

Expires: August 15, 2023

NADIM II: Neoadjuvant Nivo + CT
NADIM II: Survival Results From Phase II Study of Nivolumab + Chemotherapy vs Chemotherapy as Neoadjuvant Treatment for Resectable IIIA-B NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 18, 2022

Expires: August 17, 2023

Faculty

cover img faculity

Wade T. Iams, MD, MSCI

Assistant Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

cover img faculity

Heather Wakelee, MD

Associate Professor of Medicine, Oncology
Department of Medicine/Oncology
Stanford University/Stanford Cancer Institute
Stanford, California

Provided by

ProCE Banner

Supporters

Amgen, Inc.

Genentech, a member of the Roche Group

Merck Sharp & Dohme Corp.

Turning Point Therapeutics Inc